NxStage Establishes New Scientific Advisory Board to Build Clinical Evidence and Drive Adoption of Home Hemodialysis Therapy
Leading dialysis manufacturer forms group of esteemed experts to advance leadership and the standard of care
LAWRENCE, Mass., May 4, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, today announced the Company's new Chronic Scientific Advisory Board, an esteemed group of thought leaders focused on evaluating and advancing home dialysis therapies. Senior Medical Advisor, Dr. Allan J. Collins, will lead the distinguished board of nephrologists and cardio renal experts in actively defining, developing and conducting strategic data analyses that promote the efficacy, safety, and benefits of home hemodialysis (HHD) therapy with the NxStage System One.
Board members and affiliations include:
- Allan Collins, MD - Senior Medical Advisor of NxStage Medical, Inc.
- Chris Chan, MD – University Health Network, Toronto, Canada
- Michael A. Kraus, MD – Indiana University School of Medicine, Clarian Health
- Peter McCullough, MD – Baylor University Medical Center
- Jose Morfin, MD – UC Davis School of Medicine
- John Burkart, MD – Wake Forest University Medical Center
- Mike Copland, MD – University of British Columbia, Vancouver General Hospital
- Richard Fluck, MD – Royal Derby Hospital, Derby, United Kingdom
- Sheru Kansal, MD – Cleveland Clinic
- Paul Komenda, MD – Seven Oaks General Hospital, Winnipeg, Canada
- George Bakris, MD - University of Chicago Medicine
This new panel will continue to build the body of evidence to advance adoption of therapy with the NxStage® System One™. Through their findings, the board will seek to highlight the benefits of HHD therapy and advance the quality of dialysis care. The group will also advise NxStage on other focus items in its innovation pipeline, specifically with new perspectives related to peritoneal dialysis and alternative treatment applications.
"NxStage's selection of outstanding clinical leaders to develop critical impactful data is a major step toward enhancing access to this differentiated therapy option," said Dr. Collins. "NxStage is committed to significant innovation in dialysis care, and the impact its technologies can and will have are life-changing. It's an honor that this prestigious group of nephrologists and cardio renal experts from around the world has chosen to join me in this important role. Through extensive clinical research, we expect to demonstrate the benefits of these advancements and help to guide further innovation needed so that we may advance patient care."
"Over the years, we've shown that HHD with the System One is not just another home alternative, but a differentiated therapy with clinically significant benefits," said NxStage President, Joe Turk. "Our trusted clinician advisors have always served a critical role in helping to define the data we need to show and how these may be communicated to advance therapy adoption. We thank our outgoing board for their years of commitment, and are incredibly excited to benefit from this new board's diverse experience and unique backgrounds in the years to come."
To learn more about NxStage's Scientific Advisory Board members, please visit http://www.nxstage.com/ourcompany/scientific-advisory-board.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
[email protected]
Tel: (978) 332-5923
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article